MCP
BBNX

Meridiem Capital Partners’s Beta Bionics BBNX Stock Holding History

Meridiem Capital Partners’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-73,386
Closed -$1.46M – 110
2025
Q3 		$1.46M Buy
+73,386
New +$1.29M 0.09% 66

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Meridiem Capital Partners's BBNX Position: Q4 2025 in Review

Meridiem Capital Partners sold out of Beta Bionics (BBNX) in Q4 2025, closing a stake of 73,386 shares — an estimated $1.46M sold.

Meridiem Capital Partners first reported a position in BBNX in Q3 2025 and held it in 1 quarter. The position peaked at $1.46M in Q3 2025. 158 funds tracked by Wall St. Rank hold BBNX as of Q4 2025.

  • Meridiem Capital Partners reported no remaining Beta Bionics position as of Q4 2025 after selling out during the quarter.
  • Meridiem Capital Partners sold 73,386 Beta Bionics shares in Q4 2025, an estimated $1.46M.
  • Meridiem Capital Partners first reported a position in Beta Bionics in Q3 2025 and held it in 1 quarter.
  • Meridiem Capital Partners's Beta Bionics position peaked at $1.46M in Q3 2025.
  • 158 funds tracked by Wall St. Rank held Beta Bionics as of Q4 2025.

Based on Meridiem Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.